Changes in psychopharmacological treatment strategies in schizophrenia;Veränderungen psychopharmakologischer behandlungsstrategien bei schizophrenie

Neuropsychiatrie

Volumn 17, Issue 1, 2003, Pages 21-28

  Kurz, M ^a   Hausmann, A ^a   Honeder, M ^a   Kemmler, G ^a   Kurzthaler, I ^a   Walch, T ^a   Wechdorn, H ^a   Fleischhacker, W W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Inpatient treatment; Psychopharmacotherapy; Schizophrenia; Treatment guide lines

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE; ZOTEPINE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; STANDARD;

EID: 0043026946     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 154, 1-63 (1997).
2. Baldessarini R.J. et al.: Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am. J. Psychiatry 152, 1038-1044 (1995).
3. Chong S.A. et al.: Effect of clozapine on polypharmacy. Psychiatr. Serv. 51, 250-252 (2000).
4. Fleischhacker W.W. et al.: Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J. Clin. Psychiatry 55 (Suppl. b), 78-81 (1994).
5. Gaebel W., S. Marder: Conclusions and treatment recommendations for the acute episode in schizophrenia. Int. Clin. Psychopharmacol. 11, 93-100 (1996).
6. Geddes J. et al.: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321, 1371-1376 (2000).
7. Glikman J. et al.: Assessing the impact of a consensus conference on long-term therapy for schizophrenia. Int. J. Technol. Assess. Health Care 16, 251-259 (2000).
8. Kane J.M. et al.: Guidelines for depot antipsychotic treatment in schizophrenia. Eur. Neuropsychopharmacol. 8, 55-66 (1998).
9. Kiivet R.A. et al.: Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br. J. Clin. Pharmacol. 40, 467-476 (1995).
10. Kissling W.: The current unsatisfactory state of relapse prevention in schizophrenic psychoses suggestions for improvement. Clin. Neuropharmacol. 14, 33-44 (1991).
11. Kurz M. et al.: Efficacy of medium-dose clozapine for treament-resistant schizophrenia. Am. J. Psychiatry 152, 11 (1995).
12. Lehman A.F., D.M. Steinwachs: Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr. Bull. 24, 1-10 (1998).
13. Lehman A.F., D.M. Steinwachs: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr. Bull. 24, 11-32 (1998).
14. Lieberman J.A.: Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin. Psychiatry 57, 68-71 (1996).
15. Meise U. et al.: Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus? Schizophr. Bull. 20, 215-225 (1994).
16. Müller R. et al.: "More is less": a retrospective study of haloperidol dosages in acute schizophrenia. Psychiatr. Prax. 27, 69-73 (2000).
17. Remington GJ. et al.: Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy. Can. J. Psychiatry 38, 159-161 (1993).
18. Remington G et al.: Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psychiatr. Serv. 52, 96-98 (2001).
19. SPSS: Statistical Package for the Social Sciences. SPSS Inc., Chicago 1989-1999.
20. Vander Zwaag C et al.: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. J. Psychiatry 153, 1579-1584 (1996).
21. Walkup J.T. et al.: Patients with schizophrenia at risk for excessive antipsychotic dosing. J. Clin. Psychiatry 61, 344-348 (2000).
22. Weiser M. et al.: Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr. Res. 15, 81-89 (2000).